

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

**In re the Application of:  
WADE S. BLAIR, ET AL.**

**Serial No.: 10/599,982**

**Confirmation No.: 7735**

**Filed: October 16, 2006**

**For: HIV-1 VIRION MATURATION  
INHIBITORS, COMPOSITIONS AND  
TREATMENTS USING THE SAME**

**Group Art Unit: TBA**

**Examiner: TBA**

Mail Stop: Amendment  
Commissioner For Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT****UNDER 37 C.F.R. § 1.97****37 CFR § 1.97(b)**

- The Information Disclosure Statement submitted herewith is being filed within three months of the filing date of a national application other than a continued prosecution application under § 1.53(d); within three months of the date of entry of the national stage as set forth in § 1.491 in an international application; before the mailing of a first Office Action on the merits; or before the mailing of a first Office Action after the filing of a request for continued examination under § 1.114.

**37 CFR § 1.97(c)**

- The Information Disclosure Statement submitted herewith is being filed after three months of the filing date of a national application other than a continued prosecution application under § 1.53(d); after three months of the date of entry of the national stage as set forth in § 1.491 in an international application; after the mailing of a first Office Action on the merits; or after the mailing of a first Office Action after the filing of a request for continued examination under § 1.114, but before the mailing date of (1) a Final Action under § 1.113; (2) a Notice of Allowance under § 1.311; or (3) an action that otherwise closes prosecution in the application. The Commissioner is hereby authorized to charge the fee as set forth in § 1.17(p) to Deposit Account Number 500329.

- Applicant requests that the Examiner consider the following copending applications:

Application Serial No.	Filing Date

- Copies of these copending applications are enclosed.
- Applicant hereby requests consideration of the Information Disclosure Statement, PTO/SB/08, submitted herewith. Copies of the cited references, except as noted below, are enclosed.
- This application is a continuation, divisional or continuation-in-part of Serial No. ██████████. Copies of the cited references, if not enclosed, are available in the file of the parent application or parents thereof.
- Copies of U.S. Patents and U.S. Patent Application Publications are not enclosed. (waiver of 37 CFR 1.98(a)(2)(iii) pursuant to 37 CFR 1.183).
- Applicant hereby requests consideration of the enclosed International Search Report, which was received in a related international patent application.

The Commissioner is hereby authorized to charge any fee deficiency, including any fee required under 37 C.F.R. § 1.17(p), or credit any overpayment, to Deposit Account Number 500329. A duplicate copy of this form is enclosed.

Respectfully submitted,

Date: Nov. 16, 2006

  
Keith D. Hutchinson  
Keith D. Hutchinson  
Attorney For Applicant  
Registration No. 43,687

Agouron Pharmaceuticals, Inc./A Pfizer Company  
Patent Department  
10555 Science Center Drive  
San Diego, California 92121  
Phone: (858) 526-4608  
Fax: (858) 678-8233